Novartis’ Leqvio shows up to 50% cholesterol reduction over six years
Data from the open-label Phase III extension study showed LDL-C levels reduced by half in 80% of the patients receiving twice-yearly treatment of Leqvio.
Clinical Trials Arena Excellence Awards
Enter the Excellence Awards today! This program offers multiple benefits, such as gaining visibility among the market, your employees, and prospective clients for your achievement. To learn more about benefits, entry details, and available marketing packages, download the Research Guide.
